戊聚糖多硫酸酯黄斑病变:停药后疾病进展4年前瞻性研究的最终结果
这项单机构前瞻性病例系列纳入12名参与者共23眼,在停用戊聚糖多硫酸酯后每年随访4年,发现视功能与视网膜结构缺陷持续进展,包括最佳矫正视力下降、微视野阈值降低、阅读速度减慢及新发黄斑区完全性视网膜色素上皮和 outer retinal 萎缩,提示停药后病变仍长期进展。
要点
- 停药4年间中位ETDRS最佳矫正视力下降5个字母(P=0.005),暗视/中视微视野阈值亦显著降低。
- 基线时9眼(39%)已有黄斑区完全性视网膜色素上皮和 outer retinal 萎缩,研究结束时剩余眼中5眼(35.7%)新发该萎缩。
- 萎缩病灶中位线性增长速率为0.23 mm/年,患者报告结局量表评分4年间显著下降。
核心结论
- 这项前瞻性研究显示,戊聚糖多硫酸酯黄斑病变在停药后很长时间内,广泛的功能与结构缺陷仍持续进展。
- 作者认为这些发现应有助于指导戊聚糖多硫酸酯的处方模式、患者咨询和疾病监测策略。
研究设计与样本
- 单机构前瞻性病例系列,纳入埃默里眼科中心确诊戊聚糖多硫酸酯黄斑病变的12名参与者共23眼。
- 参与者于2018年12月1日至2019年12月1日入组,每年收集数据,共4年。
- 主要结局指标为视功能与视网膜结构的变化。
主要发现
- 12名参与者中11名(91.7%)为女性,入组时中位年龄58岁。
- 基线中位ETDRS最佳矫正视力字母评分为83,4年中位变化为-5个字母(P=0.005)。
- 中视微视野平均阈值与降低阈值百分比4年中位变化分别为-5.4 dB(P=0.003)和48.6%(P=0.004)。
- MNREAD各项指标在2年和4年评估时均下降,最大阅读速度中位变化为-21词/分钟(P=0.007)。
- NEI-VFQ-39与LLQ复合评分4年间显著下降;基线时9眼(39%)有黄斑区完全性视网膜色素上皮和 outer retinal 萎缩,研究结束时剩余眼中5眼(35.7%)新发该萎缩。
临床怎么用
- 原文结论指出这些发现应有助于指导戊聚糖多硫酸酯的处方模式、患者咨询和疾病监测策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report the long-term disease course of pentosan polysulfate (PPS) maculopathy following drug cessation. DESIGN: Single-institution, prospective case series. METHODS: 23 eyes of 12 participants seen at the Emory Eye Center with a diagnosis of PPS maculopathy were included in our study. Participants were enrolled between December 1, 2018, and December 1, 2019, and data were collected annually for four years. MAIN OUTCOMES AND MEASURES: Changes in visual function and retinal structure were the primary outcomes measured. Visual function was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA), ETDRS low-luminance visual acuity (LLVA), Minnesota low-vision reading (MNREAD) performance, contrast sensitivity, mesopic and scotopic microperimetry, and dark adaptometry. Patient reported outcomes were assessed with the National Eye Institute Visual Function Questionnaire (NEI-VFQ-39) and Low Luminance Questionnaire (LLQ). Structural outcomes included the presence of complete retinal pigment epithelium and outer retinal atrophy (cRORA), atrophic lesion size (in mm2), macular central subfield thickness (CST), and subfoveal choroidal thickness (SFCT). RESULTS: Of the 12 participants, 11 (91.7%) were female, with a median age at enrollment of 58 years. The median ETDRS BCVA letter score at baseline was 83, with a median change of -5 letters over 4 years (P = 0.005). The median 4-year change in mesopic microperimetry average threshold and percent reduced threshold was -5.4 dB (P = 0.003) and 48.6% (P = 0.004), respectively. MNREAD performance (assessed at 2 and 4 years) declined across all measures, with a median maximum reading speed change of -21 words per minute (P = 0.007). NEI-VFQ-39 and LLQ composite scores significantly decreased over 4 years. At baseline, 9 eyes (39%) had macular cRORA. By the study's end, 5 of the remaining eyes (35.7%) developed new-onset cRORA. The median linearized growth rate of atrophic lesions was 0.23 mm/year. The median 4-year change of CST and SFCT was -7.0 µm (P = 0.055) and -22.0 µm (P = 0.610), respectively. CONCLUSION: This prospective study demonstrates continued progression of broad-ranging functional and structural deficits in PPS maculopathy long after drug cessation. These findings should inform PPS prescribing patterns, patient counseling, and disease monitoring strategies.
引用
- Hall BP, Shiromani S, Jung EH, et al. Pentosan Polysulfate Maculopathy: Final Outcomes from a 4-Year Prospective Study of Disease Progression after Drug Cessation. Am J Ophthalmol. 2024. PMID: 39667696. doi:10.1016/j.ajo.2024.12.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。